Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 6/20 | 0.64 |
| ▸ | GABBR1 | Q9UBS5 | 6/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SCN4A | P35499 | 2/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390880 | 0.84 | GABBR2 (0.49) | GABBR2GABBR1CYP1A2CYP3A4TSHR | |
| SCHEMBL6034394 | 0.81 | GABBR2 (0.42) | GABBR2GABBR1 | |
| SCHEMBL6033150 | 0.81 | GABBR2 (0.42) | GABBR2GABBR1CYP2D6CA1CA2 | |
| SCHEMBL6033113 | 0.81 | GABBR2 (0.42) | GABBR2GABBR1CYP1A2CA1CA2 | |
| SCHEMBL6033156 | 0.80 | GBA1 (0.49) | GABBR2GABBR1MEN1KMT2A | |
| SCHEMBL27721990 | 0.80 | GBA1 (0.49) | SCN4ACYP2C19 | |
| SCHEMBL2486785 | 0.80 | GBA1 (0.49) | SCN4ACYP2C19 | |
| SCHEMBL27662674 | 0.79 | GABBR2 (0.45) | GABBR2GABBR1MAPTSMN1; SMN2CA1 | |
| SCHEMBL339758 | 0.78 | GABBR2 (1.00) | GABBR2GABBR1CYP1A2CYP3A4TSHR | |
| SCHEMBL339757 | 0.78 | GABBR2 (1.00) | GABBR2GABBR1CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1882375-A | treatment of amyloid-and epileptogenesis-related diseases | NEUROCHEM INTERNAT LTD (CH) | 2006-12-20 | — | — | CN | disclosed |
| EP-1635909-A2 | TREATMENT OF AMYLOID- AND EPILEPTOGENESIS-ASSOCIATED DISEASES | Neurochem (International) Limited (CH) | 2006-03-22 | — | — | EP | disclosed |
| US-20050038000-A1 | Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2005-02-17 | — | — | US | disclosed |
| WO-2005000406-A2 | TREATMENT OF AMYLOID- AND EPILEPTOGENESIS-ASSOCIATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038000-A1 | Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases | APP, PSEN1, PSEN2 | GABBR2 203/4885GABBR1 144/4885CYP1A2 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.